Isolation and mutagenesis of streptokinase producing bacteria.
Abdelghani, Thaer Taleb Abed
|Publication:||Name: American Journal of Immunology Publisher: Science Publications Audience: Professional Format: Magazine/Journal Subject: Biological sciences Copyright: COPYRIGHT 2005 Science Publications ISSN: 1553-619X|
|Issue:||Date: Oct, 2005 Source Volume: 1 Source Issue: 4|
|Geographic:||Geographic Scope: United States Geographic Code: 1USA United States|
Abstract: Of 103 [beta]-haemolytic Streptococci (with haemolytic
activity) in total were isolated from different samples of blood and
biomass from infected throat, 47 isolates exhibited streptokinase (SK)
activity. T3, identified as a new variant of Streptococcus equisimilis,
was found to be excellent SK producer in submerged fermentation and was
selected for strain improvement studies. This strain was mutagenized by
UV and N-methyl-N'-nitro-N-nitroso guanidine (NTG). The isolation
of mutants and the SK activity of selected mutants were described. The
SK yield of the best UV mutant AUV10 was 120% higher than the wild
strain (T3). Also, the SK yield of the best NTG mutant NUV7 was 146%
higher than the wild strain (T3). The results indicated that UV and NTG
were effective mutagenic agents for strain improvement of S. equisimilis
T3 for enhanced SK productivity.
Key words: Streptokinase (SK), screening, isolation, mutagenesis, bacteria
A blood clot (thrombus) developed in the circulatory system can cause vascular blockage leading to serious consequences including death. A healthy hemostatic system suppresses the development of blood clots in normal circulation, but reacts extensively in the event of vascular injury to prevent blood loss. Outcomes of a failed hemostasis include stroke, pulmonary embolism, deep vain thrombosis and acute myocardial infraction. Pathologies involving a failure of hemostasis and the development of clot require clinical intervention consisting of intravenous administration of thrombolytic agents (Collen et al., 1988, Collen, 1990 and Francis and Marder, 1991; Banerjee et al., 2004). Streptokinase is one such agent. Other thrombolytic or fibrinolytic agents include urokinase and the tissue type plasminogen activator (tPA).
Numerous trails have been conducted to compare the clinical efficacy of recombinant tPA and streptokinase. Generally, these investigations have not revealed a clear preference for either drug. Streptokinase is as effective as recombinant tPA in treating acute myocardial infarction (Sherry and Marder, 1991), and it is certainly more cost-effective; however, its use is not risk free. In view of the relatively recent availability of the competing recombinant tPA, skepticism is being expressed about the continued viability of streptokinase therapy (Sane and Little, 1998 and Werf, 1999). Despite this, research on streptokinase continues, and it remains a vital affordable therapy especially in the world's poorer healthcare systems.
Streptokinase (SK) is an extracellular protein produced by many strains of [beta]-haemolytic streptococci (Tillet and Garner, 1933). It facilitates lyses of blood clots by activating the plasminogen, to the fibrinolytic enzyme, plasmin. The SK has been currently used in clinical medicine as a therapeutic agent in the treatment of acute myocardial infraction following coronary thrombosis (Ko et al., 1995; Banerjee et al., 2004).
The SK has been reported that Feldman (1974), increase in yield of the SK with strain H-46A. Malke and Ferretti (1984) used brain-heart infusion (BHI) medium and got good growth of S. equisimilis H-46A. Lee et al. (1997) achieved enhanced production and secretion of SK into extracellular medium by Escherichia coli.
The increasing potential of SK application promoted us to screen for newer streptokinase-producing organisms. Also the exponential increase in the application of SK in various fields in the last few decades demands extension in both qualitative improvement and quantitative enhancement. Quantitative enhancement requires strain improvement and medium optimization for the overproduction of the enzyme, as the quantities produced by wild strains are usually too low. The spectacular success examples of strain improvement in industry are mostly attributed to the extensive application of mutation and selection. Hence, in the present work, an attempt was made to isolate streptokinase-producing bacteria and subjecting it to strain improvement by random mutagenesis (UV irradiation and NTG (N-methyl- N'-nitro-N-nitroso guanidine) treatment) to enhance SK productivity.
MATERIALS AND METHODS
Screening and Isolation of Producing Streptococci: A total of nine samples were collected in sterile containers for the systematic screening of [beta]-haemolytic Streptococci. The samples included blood and biomass from infected throat (Table 1).
In literature, several media have been suggested for the isolation of [beta]-haemolytic Streptococci such as blood agar and sodium azide (Cruickshank, 1968); crystal violet blood agar, Todd Hewitt infusion broth and PNF medium (Collee et al., 1969). Pour plate method has been used in the present work for the isolation of Streptococci.
To 45 ml of melted and cooled nutrient agar base (Hi-media, India) (55[degrees]C), sterile sheep blood was added at 10% level. To this, 0.05 ml of each test sample was mixed and poured into 6" petridishes and incubated at 37[degrees]C for 24 h. The discrete colonies with clear hydrolysis zones were picked up, transferred into blood agar slants and incubated at 37[degrees]C for 24 hr. The microorganisms, which formed clear zones after incubation, were selected. The selected isolates were subjected for extracellular SK production by submerged fermentation.
Morphological and taxonomic characteristics of the promising isolated strain was examined by by Bergey's Manual of Determinative Bacteriology, 1974, Bergey's Manual of Systematic Bacteriology, 1992, Mackie and McCartney Practical Medical Microbiology (Collee et al., 1969), District Laboratory Manual Practice in Tropical Countries (Monica, 2000), Medical Microbiology (Cruickshank, 1968) and Laboratory Manual on Fundamental Principles of Bacteriology (Salle, 1948).
Strain Improvement Studies:
UV Irradiation: Strain improvement for the selected parent strain, was done by mutation and selection. The wild strain was subjected to UV irradiation. Mutation frequency was mentioned to be high when the survival rates were between 10 and 0.1%. The dose survival curve was plotted for selecting the mutants between 10 and 0.1% rate.
The spore suspension of wild strain was prepared in phosphate buffer (pH 8.0) and four ml quantities of the spore suspension were pipetted aseptically into sterile petri dishes of 80 mm diameter having a flat bottom. The exposure to UV light was carried out in a "Dispensing--Cabinet" fitted with TUP 40w Germicidal lamp which has about 90% of its radiation at 2540-2550 [A.sup.0]. The exposure was carried out at distance of 20.0 cm away from the center of the Germicidal lamp (UV light source) with occasional shaking. The exposure times were 0, 2, 4, 6, 8 and 10 min. Each UV exposed cell suspension was stored in dark overnight to avoid photo reactivation, then was serially diluted in phosphate buffer and plated on PDA medium. The plates were incubated for 24 hr at 37[degrees]C and the numbers of colonies in each plate were counted. Each colony was assumed to be formed from a single cell. A total of 15 colonies (designated as AUV1 to AUV15) were selected from the plates showing less than 1% survival rate (6 and 8 min UV exposure time) and tested for SK production. Among the selectants, the best UV mutant strain was used for further studies.
NTG Treatment: The NTG is considered to be a very effective mutagen (Adelberg et al., 1965 and Cerdia-Olmedo and Hanawalt, 1968). Its action has been attributed to its decomposition products (Cerdia-Olmedo and Hanawalt, 1968). The best UV mutant (AUV10) was used for NTG treatment. The spore suspension was prepared in the same manner as described earlier. To a 9 ml of spore suspension, 1 ml of sterile solution of NTG (3 mg/ml in phosphate buffer) was added. The reaction was allowed to proceed. Samples were withdrawn from the reaction mixture at intervals of 30, 60, 90, 120, 150 and 180 min and immediately centrifuged for 10 min at 5000 rpm and the supernatant solution was decanted. Cells were washed three times with sterile water and resuspended in 10 ml of sterile phosphate buffer. The samples were serially diluted in the same buffer and plated over PDA as mentioned earlier. A total of 15 colonies (designated as NUV1 to NUV15) were selected from the plates showing less than 1% survival rate (120 and 150 min NTG treated spore suspension) and tested for SK production.
Shake Flask Fermentations: The growth of the isolate cultivated on nutrient agar slants was scrapped with 5 ml of sterile distilled water and transferred into 250 ml Erlenmeyer flask containing 45 ml of production medium (Baewald, 1975) [(g/L): glucose, 5.0; yeast autolyzate, 5.0; K[H.sub.2]P[O.sub.4], 2.5; K[H.sub.2]P[O.sub.4], 2.5; MgS[O.sub.4].7[H.sub.2]O, 0.4; NaHC[O.sub.3], 1.0; C[H.sub.3]COONa.3[H.sub.2]O, 1.0; FeS[O.sub.4].7[H.sub.2]O, 0.02 and Mn[Cl.sub.2].4[H.sub.2]0, 0.02 with pH 7.5.] in 250 ml Erlenmeyer flask. The flasks were incubated at 37[degrees]C for 24 hr in a shaker incubator (120 rpm). The culture broth was then filtered and the clear filtrate was used as the crude enzyme source.
SK Assay: The SK activity was determined using modified Holmstrom method (Holmstrom, 1965). One unit (U) is defined as quantity of enzyme that will liquefy a standard clot of fibrinogen, plasminogen and thrombin at pH 7.5 at 37[degrees]C in 18 h. All the experiments were conducted in triplicate.
About 103 Streptococci (with haemolytic activity) in total were isolated from the above 9 samples. The distribution of Streptococci in different samples is shown in Table 1. The isolates were pooled together and cultures, which appeared identical to the naked eye, were eliminated. All the isolates were tested for their [beta]-haemolytic activity on PNF selective medium. About 47 [beta]-haemolytic positive isolates were obtained (identical hydrolysis zone). Among these, 20 isolates showed moderate to good haemolytic activity. These 20 isolates (human source) were selected to study their SK activities. Among the 20 active isolates, isolate T3 gave highest SK activity (681 U/ml). As such, this isolate (T3) was subsequently selected for the taxonomic studies.
Proper identification and characterization of microorganisms is a very important because it expands the scope for exploitation of industrially important products. To establish the novelty or otherwise of the present isolates with those of reported in the literature, the various morphological, cultural and biochemical characteristics of the isolated organisms were compared with the descriptions of the numerous Streptococcus species cited in the literature. Also Lancefield grouping was carried out. The literature survey includes Bergey's Manual of Systematic Bacteriology (1992), Bergey's Manual of Determinative Bacteriology (1974), Mackie and McCartney Practical Medical Microbiology (Collee et al., 1969), District Laboratory Practice in Tropical Countries (Monica, 2000), Medical Microbiology (Cruickshank, 1968) and Laboratory Mannual on Fundamental Principles of Bacteriology (Salle, 1948) Biological and Microbiological abstracts and all other relevant journals.
The characteristics of our isolate T3 were compared with that of the reference cultures. The reference cultures used are: H46A strain, a group C Streptococci procured from Dr. Malke, Germany and NZ131, a group A Streptococci procured from Dr. Ferretti, Oklahoma University, USA.
The cultural characteristics, physiological and biochemical properties, sugar fermentation, growth in different media and resistance to various inhibitors are shown in Table 2.
The most important characteristics of the strain T3 are summarized as follows: The cells are spherical in shape, with moderately long chains in liquid media. There are no endospores or pellicle formation in broth media. They are non-motile and gram-positive. There was no growth at a temperature of 10[degrees] or 45[degrees]C, at initial pH 9.6 and heating the cells at 60[degrees]C for 30 min. Growth was not observed in media containing 0.1% methylene blue, 6.5% sodium chloride and 40% bile. Good growth was observed in media containing sodium azide or in crystal violet blood agar medium and potassium tellurite. The strain exhibited negative litmus milk reduction test. It showed a positive [beta]-haemolysis and PNF tests. The minimum inhibitory concentration (MIC) of the strain with benzyl penicillin was 0.02[micro]g/ml. The strain exhibited negative CAMP test. The isolate did not hydrolyze gelatin, hippurate and esculin. It hydrolyzed starch and arginine. It exhibited negative tests of pyruvate fermentation, Voges-Proskauer (acetoin production), catalase and hydrogen sulphide production. The strain showed methyl red and nitrate reduction tests positive.
The final pH in glucose fermentation was 4.7 and no gas was formed. The acid formation was positive from salicin, trehalose, cellobiose, glycerol, galactose, fructose, xylose, mannose, sucrose, maltose and glucose. The acid formation was negative from inulin, lactose, mannitol, raffinose, ribose, sorbitol, melibiose, arabinose, inositol, erythritol, dulcitol, dextrin, adonitol, rhamnose, soluble starch and potato starch.
The wild strain of S. equisimilis T3 was subjected to strain improvement programme with a view to obtain increased SK production and to achieve greater stability of the organism. The first method chosen was UV irradiation.
The selected mutants were provided with the code number AUV1 to AUV15 and these mutants were tested for their SK producing capabilities (Table 3). The results indicated that among UV mutants, AUV10 was found to be the highest SK producer (821 U/ml) and it was 120% higher yield over the wild strain (681 U/ml). The mutant, AUV10 was selected for further strain improvement studies using NTG.
The selected UV mutant, AUV10 was subjected to NTG treatment. A total of 15 mutants were selected, and they were provided with the code numbers NUV1 to NUV15. These were evaluated for their SK production capacities (Table 3). The results indicated that the mutant NUV7 was the highest SK yielding strain (996 U/ml). Thus the NTG treatment results a mutant that produced 146% higher yield of SK over the wild strain (681 U/ml), which is a significant increase of yield.
A total of 103 isolates were obtained from nine samples of blood and biomass from infected throat. Of them, 20 isolates showed moderate to good SK activity and the strain T3, which gave maximum enzyme activity, was selected for detailed taxonomical studies.
A detailed survey of the literature indicated that our isolate T3 belongs to Streptococci group C. The data indicated that our isolate is closure to S. equisimilis. A detailed comparison of our isolate was made to establish its novelty or otherwise. The data is presented in Table 2. However, some significant qualitative and quantitative differences could be noticed. Our isolate T3 differed from the reference culture in the following aspects: Good growth was observed for our isolate T3 on sodium azide and crystal violet blood agar media while moderate growth was observed for the reference culture on the same media. The MIC against benzyl penicillin of our isolate was found to be 0.02 [micro]g/ml while it was 0.04 [micro]g/ml for reference. Regarding the biochemical reactions, our isolate has a slight amylolytic activity while reference culture showed no amylolytic activity. Esculin hydrolysis was negative for our isolate while it was delay activity for reference. Reference culture produced acid from lactose and ribose while our isolate did not produce. In view of these significant differences, it is proper to consider our isolate T3 is a new variant of S. equisimilis.
The wild strain of S. equisimilis was subjected to strain improvement studies. From the results (Table 3), it is evident that UV and NTG were effective mutagenic agents for strain improvement of S. equisimilis T3. By employing these techniques, a superior mutant (NUV7) with a productivity of 146% (681 to 996 U/ml) higher than that of the wild strain was obtained.
The results revealed that UV and NTG were effective mutagenic agents for strain improvement of S. equisimilis T3 for enhanced SK productivity. It is hoped that the high yielding mutant strain of the isolate S. equisimilis T3 can be exploited commercially for large scale industrial production of SK. Also future studies will test SK in vivo, and the cloning, sequencing, and expression of the SK gene from chromosomal DNA of S. equisimilis strain T3 is proceeding.
The authors are thankful to Andhra University, Visakhapatnam, India and Council of Scientific & Industrial Research (CSIR), New Delhi, India, for providing financial support to carryout this work and awarding a senior research fellowship (Award No. 9/2 (454)/2k2, EMR.I) to Dr. Adinarayana Kunamneni.
[1.] Adelberg, E.A., Mandel, M., Chen, G.C.C., 1965. Optimal conditions for mutagenesis by Nmethyl-N-nitro-N-nitroso guanidine in Escherichia coli K12. Biochem. Biophys. Res. Commun. 18, 788-795
[2.] Baewald, G., Mayer, G., Heikel, R., Volzke, K.D., Roehlig, R., Decker, K.L., Koehler, W. and Gerlach, D., 1975. Fermentative production of Streptococcus metabolites, especially streptokinase. German patent DD 111096
[3.] Banerjee, A., Chisti, Y., Banerjee, U.C., 2004. Streptokinase--a clinically useful thrombolytic agent. Biotechnol. Adv. 22, 287-307
[4.] Cerda-Olmedo, E., Hanawalt, P.C., 1968. Diazomethane as the active agent in nitrosoguanidine mutagenesis and lethality. Mol. Gen. Genet. 101, 191-202
[5.] Collee, J.G., Fraser, A.G., Marmion, B.P., Simmons, A., 1969. Mackie and McCartney Practical Medical Microbiology, 14th ed. Churchill Livingstone, New York
[6.] Collen, D., 1990. Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator?. Ann. Intern. Med. 112, 529-538
[7.] Collen, D., Stump, D.C., Gold, H.K., 1988. Thrombolytic therapy. Annu. Rev. Med. 39, 405-423
[8.] Cruickshank, R., 1968. Medical Microbiology, 11th ed. E. and S. Livingstone Ltd., Edinburgh, UK
[9.] Feldman, L.J., 1974. Streptokinase Manufacture. German patent DE 2354019
[10.] Francis, C.W., Marder, V.J., 1991. Fibrinolytic therapy for venous thrombosis. Prog. Cardiovasc. Dis. 34 , 193-204
[11.] Holmstrom, B., 1965. Streptokinase assay on large agar diffusion plates. Acta Chem. Scand. 19, 1949-1954
[12.] Ko, J.H., Park, K., Kim, I.C., Lee, S.H., Byun, S.M., 1995. High level expression and secretion of streptokinase in Escherichia coli. Biotechnol. Lett. 17, 1019-1024
[13.] Lee, S.H., Kim, I.C., Bae, K.H., Byun, S.M., 1997. Enhanced production and secretion of streptokinase into extracellular medium in Escherichia coli by removal of 13 N-terminal amino acids. Biotechnol. Lett. 19, 151-154
[14.] Malke, H., Ferreti, J.J., 1984. Streptokinase: cloning, expression and excretion by E. coli. Proc. Natl. Acad. Sci. 81, 3557-3561
[15.] Monica, C., 2000. District Laboratory Practice in Tropical countries, Vol. II, Cambridge University Press, Cambridge, UK
[16.] Salle, A.J., 1948. Laboratory Mannual on Fundamental Principles of Bacteriology, 3rd ed. McGraw-Hill Book Company, INC, London
[17.] Sane, D.C., Little, W.C., 1998. Is time running out on streptokinase?. J. Am. Coll. Cardiol. 31, 780-782
[18.] Sherry, S., Marder, V.J., 1991. Streptokinase and recombinant tissue plasminogen activator (rt-PA) are equally effective in treating acute myocardial infarction. Ann. Intern. Med. 114, 417-423
[19.] Tillet, W.S., Garner, R.L., 1933. Fibrinolytic activity of hemolytic Streptococci. J. Exp. Med. 58, 485-491
[20.] Werf, F.V.D., 1999. Streptokinase ... never again. Eur. Heart J. 20, 1215
Thaer Taleb Abed Abdelghani, Adinarayana Kunamneni, Poluri Ellaiah
Pharmaceutical Biotechnology Division, Department of Pharmaceutical Sciences Andhra University, Visakhapatnam--530 003, India.
Corresponding Author: Dr. Adinarayana Kunamneni, Department of Pharmaceutical Sciences, Andhra University, India, Tel: +91 891 2505519, Fax: ++91 891 2755547
Table 1: Sources of samples (distribution of Streptococci in different samples) Sample Source No. of S.No No. of culture Disease isolates 1 HB1 Human blood Septicaemia 9 2 HB2 Human blood Septicaemia 10 3 HB3 Human blood Septicaemia 14 4 HT1 Human throat Acute tonsillitis 11 5 HT2 Human throat Acute tonsillitis 10 6 HT3 Human throat Scarlet fever 12 7 HB4 Human blood Scarlet fever 13 8 SB5 Sheep blood Scarlet fever 11 9 SB6 Sheep blood Scarlet fever 13 Total 103 Table 2: Morphological, metabolic, biochemical and sugar fermentation tests of the isolate T3 and reference cultures Morphological and metabolic tests T3 H46A NZ 131 Group G Haemolysis + + + + PNF test + + + + Shape of the cells S S S O Endospores - - - - Motility - - - - Gram-staining + + + + Growth at 10[degrees]C - - - - 45[degrees]C - - - - pH 9.6 - - - - Heat tolerance at 60[degrees]C - - - - for 30 min Growth in media containing Methylene blue (0.1% in milk) - - - - Sodium chloride (6.5%) - - - - Bile salt (40%) - - - - Potassium tellurite + + + + Growth in Sodium azide medium G M G No Crystal violet blood agar G M G No Litmus milk reduction test - - - - MIC (penicillin G, [micro]g/ml) - - - - cAMP test 0.02 0.04 0.006 0.004-0.006 Biochemical tests: Hydrolysis of Gelatin - - [+ or -] - Starch + [+ or -] - - Hippurate - - - - Esculin - [+ or -] [+ or -] [+ or -] Arginine + + + + Pyruvate fermentation - - - - Voges-Proskauer - - - - Methyl red + + + + Hydrogen sulphide - - - - Catalase - - - - Nitrate reduction + + + + Lancefield grouping C C A G Sugar Morphological and fermentation metabolic tests tests T3 H46A NZ 131 Group G Haemolysis Inulin - - - + PNF test Lactose - + + + Shape of the cells Mannitol - - - - Endospores Raffinose - - - - Motility Ribose - + - + Gram-staining Salicin + + + - Growth at Sorbitol - - - - 10[degrees]C Trehalose + + + + 45[degrees]C Cellobiose + + + - pH 9.6 Melibiose - - - - Heat tolerance at 60[degrees]C Glycerol + + - + for 30 min Growth in media containing Arabinose - - - No Methylene blue (0.1% in milk) Inositol - - - - Sodium chloride '(6.5%) Galactose + + + No Bile salt (40%) Erythritol - - - No Potassium tellurite Dulcitol - - - No Growth in Dextrin - - + No Sodium azide medium Adonitol - - - No Crystal violet blood agar Litmus milk reduction test Rhamnose - - - No MIC (penicillin G, [micro]g/ml) Potato starch - - - No cAMP test Fructose + + + No Xylose + + + No Biochemical tests: Mannose + + + No Hydrolysis of Sucrose + + + + Gelatin Maltose + + + + Starch Glucose + + + + Hippurate Final pH in gluose broth 4.7 4.9 5.5 No Esculin Arginine Pyruvate fermentation Voges-Proskauer Methyl red Hydrogen sulphide Catalase Nitrate reduction Lancefield grouping G: Good growth, M: Moderate growth, No: Not reported, S: Spherical, O: Oval, +: Positive reaction, -: Negative reaction Table 3: UV mutants and NTG treated selectants from AUV 10 and their SK activity NTG UV mutants SK activity (U/ml) mutants SK activity (U/ml) AUV1 462.0 [+ or -] 12.1 NUV1 673.0 [+ or -] 7.6 AUV2 516.0 [+ or -] 15.0 NUV2 668.0 [+ or -] 6.3 AUV3 458.0 [+ or -] 14.0 NUV3 684.0 [+ or -] 6.9 AUV4 503.0 [+ or -] 14.4 NUV4 717.0 [+ or -] 6.1 AUV5 402.0 [+ or -] 13.9 NUV5 740.0 [+ or -] 7.3 AUV6 494.0 [+ or -] 15.1 NUV6 469.0 [+ or -] 5.9 AUV7 635.0 [+ or -] 16.2 NUV7 996.0 [+ or -] 8.5 AUV8 576.0 [+ or -] 16.1 NUV8 772.0 [+ or -] 9.2 AUV9 580.0 [+ or -] 16.3 NUV9 597.0 [+ or -] 6.0 AUV10 821.0 [+ or -] 17.4 NUV10 663.0 [+ or -] 7.1 AUV11 404.0 [+ or -] 16.0 NUV11 499.0 [+ or -] 6.3 AUV12 678.0 [+ or -] 15.7 NUV12 677.0 [+ or -] 7.4 AUV13 583.0 [+ or -] 16.1 NUV13 467.0 [+ or -] 5.7 AUV14 434.0 [+ or -] 13.5 NUV14 366.0 [+ or -] 3.5 AUV15 392.0 [+ or -] 12.3 NUV15 716.0 [+ or -] 3.4 T3 (Wild strain) 681.0 [+ or -] 16.4
|Gale Copyright:||Copyright 2005 Gale, Cengage Learning. All rights reserved.|